跳到正文
原文
Nature Medicine· Ryan J. Sullivan·· 28 天前精选AI 评分77

invikafusp alfa在实体瘤中的I/II期START-001试验结果公布

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

AI 导读

invikafusp alfa在实体瘤中的I/II期START-001试验中表现出良好的耐受性,并确定了推荐剂量,同时在免疫热和冷肿瘤中均显示出初步疗效信号。研究在ESMO 2026会议上展示,针对Vβ6/Vβ10 T细胞亚群的双T细胞激动剂。

推荐理由

原文显示该药物在I/II期试验中表现出初步疗效信号,为后续研究提供剂量选择依据。

正文 · 原文

Nature Medicine, Published online: 23 October 2026; doi:10.1038/s41591-026-04711-0

As presented at the European Society for Medical Oncology Congress 2026, in a phase 1/2 trial in participants with solid tumors, invika, a first-in-class bispecific agonistic antibody that selectively targets the prevalent Vβ6/Vβ10 T cell subsets, was well tolerated, enabling the selection of a recommended phase 2 dose for further testing, and showed a preliminary efficacy signal in both immunologically hot and cold tumors.

来源:Nature Medicine · nature.com